Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW640385/ritonavir dose-selection study in protease inhibitor-experienced adults with HIV-1
2005-001150-24Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brecanavir and ritonavir in Human immunodeficiency virus infection type 1 (5 arms), sponsored by GSK. Primary endpoint: Absolute change from Day 1 in plasma HIV-1 RNA over 15 days. Started Jun 2005; status: completed.
02
Drugs
brecanavirritonavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-001150-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001150-24.